|
|
Volumn 14, Issue 3 SUPPL., 2008, Pages
|
|
Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALENDRONIC ACID;
BISPHOSPHONIC ACID DERIVATIVE;
CALCIUM;
CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;
ESTROGEN;
ESTROGEN PLUS GESTAGEN;
GESTAGEN;
IBANDRONIC ACID;
PARATHYROID HORMONE[1-34];
RALOXIFENE;
RISEDRONIC ACID;
SALCATONIN;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
VITAMIN D;
ADULT;
AGED;
AGING;
ARTICLE;
BREAST CANCER;
CEREBROVASCULAR ACCIDENT;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY RISK;
DRUG EFFICACY;
DRUG SAFETY;
ENDOMETRIUM CANCER;
FEMALE;
HEALTH CARE QUALITY;
HIGH RISK POPULATION;
HIP FRACTURE;
HORMONE SUBSTITUTION;
HUMAN;
ISCHEMIC HEART DISEASE;
LUNG EMBOLISM;
MAJOR CLINICAL STUDY;
MANAGED CARE;
MENOPAUSAL SYNDROME;
MENOPAUSE;
MONOTHERAPY;
MULTICENTER STUDY;
POSTMENOPAUSE OSTEOPOROSIS;
PRACTICE GUIDELINE;
RANDOMIZED CONTROLLED TRIAL;
RISK BENEFIT ANALYSIS;
WOMEN'S HEALTH;
|
|
EID: 43949104132
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2008.14.s3-a.7 Document Type: Article |
|
Times cited : (18)
|
|
References (45)
|
